Evidence map›Paper›PMID 25121735›Full record

ArticlePloS one2014

Subverting ER-stress towards apoptosis by nelfinavir and curcumin coexposure augments docetaxel efficacy in castration resistant prostate cancer cells.

Aditi Mathur, Zakaria Y Abd Elmageed, Xichun Liu, Mikhail L Kostochka, Haitao Zhang, Asim B Abdel-Mageed, Debasis Mondal

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Curcumin: reclaiming the lost ground against cancer resistance.Cancer drug resistance (Alhambra, Calif.) · 2021
    Review
  7. Review
  8. Review
  9. CBeLife · 2020
    Article
  10. Article
  11. Curcumin and Cancer.Nutrients · 2019
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Aditi MathurDepartment of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana, United States of America.
Zakaria Y Abd ElmageedDepartment of Urology, Tulane University School of Medicine, New Orleans, Louisiana, United States of America.
Xichun LiuDepartment of Pathology, Tulane University School of Medicine, New Orleans, Louisiana, United States of America.
Mikhail L KostochkaPeptide Research Laboratories, Tulane University School of Medicine, New Orleans, Louisiana, United States of America.
Haitao ZhangDepartment of Pathology, Tulane University School of Medicine, New Orleans, Louisiana, United States of America.
Asim B Abdel-MageedDepartment of Urology, Tulane University School of Medicine, New Orleans, Louisiana, United States of America.
Debasis MondalDepartment of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana, United States of America.
Tulane University · US

Funding

Intramural NIH HHSNCI NIH HHS PC080811NCI NIH HHS PC081598
6 · The paper itself

Abstract

Despite its side-effects, docetaxel (DTX) remains a first-line treatment against castration resistant prostate cancer (CRPC). Therefore, strategies to increase its anti-tumor efficacy and decrease its side effects are critically needed. Targeting of the constitutive endoplasmic reticulum (ER) stress in cancer cells is being investigated as a chemosensitization approach. We hypothesized that the simultaneous induction of ER-stress and suppression of PI3K/AKT survival pathway will be a more effective approach. In a CRPC cell line, C4-2B, we observed significant (p<0.005) enhancement of DTX-induced cytotoxicity following coexposure to thapsigargin and an AKT-inhibitor. However, since these two agents are not clinically approved, we investigated whether a combination of nelfinavir (NFR) and curcumin (CUR), known to target both these metabolic pathways, can similarly increase DTX cytotoxicity in CRPC cells. Within 24 hrs post-exposure to physiologic concentrations of NFR (5 µM) and CUR (5 µM) a significantly (p<0.005) enhanced cytotoxicity was evident with low concentration of DTX (10 nM). This 3-drug combination rapidly increased apoptosis in aggressive C4-2B cells, but not in RWPE-1 cells or in primary prostate epithelial cells (PrEC). Comparative molecular studies revealed that this 3-drug combination caused a more pronounced suppression of phosphorylated-AKT and higher induction in phosphorylated-eIF2α in C4-2B cells, as compared to RWPE-1 cells. Acute exposure (3-9 hrs) to this 3-drug combination intensified ER-stress induced pro-apoptotic markers, i.e. ATF4, CHOP, and TRIB3. At much lower concentrations, chronic (3 wks) exposures to these three agents drastically reduced colony forming units (CFU) by C4-2B cells. In vivo studies using mice containing C4-2B tumor xenografts showed significant (p<0.05) enhancement of DTX's (10 mg/kg) anti-tumor efficacy following coexposure to NFR (20 mg/kg) & CUR (100 mg/kg). Immunohistochemical (IHC) analyses of tumor sections indicated decreased Ki-67 staining and increased TUNEL intensity in mice exposed to the 3-drug combination. Therefore, subverting ER-stress towards apoptosis using adjuvant therapy with NFR and CUR can chemosensitize the CRPC cells to DTX therapy.

Indexed as

AnimalsApoptosisCell Line, TumorCurcuminDocetaxelEndoplasmic Reticulum StressEpithelial CellsHumansMaleMiceMice, NudeNelfinavirPhosphatidylinositol 3-KinasesProstatic Neoplasms, Castration-ResistantProto-Oncogene Proteins c-aktTaxoidsCurcuminDocetaxelNelfinavirPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTaxoidsThapsigargin

Identifiers

PMID25121735
PMCPMC4133210
OpenAlexW2009598346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.